Pancreatic Cancer Research

ResearcherHirosaki UniversityActive in the last 2 years

Yutaro Hara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7205-1784; OpenAlex author ID A5085470055. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 5

  1. MEG3 Promoter Methylation and F11 Receptor (F11R) Overexpression Define a High-Risk Subtype of Diabetic Pancreatic Cancer. Co-author DOI 10.1016/j.modpat.2025.100953↗
  2. Dual epigenetic changes in diabetes mellitus-associated pancreatic ductal adenocarcinoma correlate with downregulation of E-cadherin and worsened prognosis. Co-author DOI 10.1002/cjp2.326↗
  3. Diabetes mellitus impacts on expression of DNA mismatch repair protein PMS2 and tumor microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jdi.13929↗
  4. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Re… Co-author DOI 10.1245/s10434-021-10920-3↗
  5. Diabetes in Humans Activates Pancreatic Stellate Cells via RAGE in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms222111716↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichi Hakamada · 5 shared papers, 2021–2026 · strength 0.86
  2. Keisuke Yamazaki · 3 shared papers, 2023–2026 · strength 0.58
  3. Keinosuke Ishido · 3 shared papers, 2022–2026 · strength 0.57
  4. Xuekai Pan · 1 shared paper, 2023 · strength 0.17
  5. Hayato Nagase · 1 shared paper, 2022 · strength 0.16
  6. Taishu Kanda · 1 shared paper, 2022 · strength 0.16
  7. Taiichi Wakiya · 1 shared paper, 2022 · strength 0.16
  8. Chiaki Uchida · 1 shared paper, 2021 · strength 0.12
  9. Takeshi Saito · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.